Painreform Ltd. (PRFX) has released an update.
PainReform Ltd. has achieved a significant milestone by enrolling 50% of the participants for the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy. The company, which targets the postoperative pain relief market with its reformulated therapeutics, aims to redefine pain management standards and offer a safer alternative to opioids. With over 200 patients enrolled across eight U.S. sites, PainReform anticipates releasing top-line data by mid-2024.
For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.
